Alain Sanchez, MD (@lain_sanchez) header
Alain Sanchez, MD (@lain_sanchez) profile picture

Rheumatologist and Internist @ABCcentromedico | Professor @TECccm Former Research Fellow, Division of rheumatology @MayoClinic, Rochester, MN

Rochester, MN
Joined September 2013
Alain Sanchez, MD retweeted
Not all bone marrow oedema is spondyloarthritis! Osteitis condensans ilii can mimic sacroiliitis on MRI. Recognising its characteristic imaging features is essential to avoid misdiagnosis. #SpA #Spondyloarthritis #OsteitisCondensansIlii
1
25
1
58
2,079
Alain Sanchez, MD retweeted
In lupus nephritis (LN), “activity” gets the spotlight—but chronic scarring often decides the long game. So: which chronicity score best predicts outcomes—NIH Chronicity Index (NIH-CI) or the Mayo Clinic Chronicity Score (MCCS)? buff.ly/tvebmPZ
1
29
56
2,944
Alain Sanchez, MD retweeted
🫁 ERS/EULAR 2026 CTD-ILD Guidelines — Key Takeaways 🔹 Covers SSc, RA, IIM, Sjögren, SLE & MCTD–ILD 🔹 Built on 25 PICO + 28 narrative questions using GRADE methodology 📌 Screening 👉 HRCT = gold standard 🚫 Do NOT replace HRCT with PFTs or lung ultrasound (high miss rates) ✅ Screen ALL SSc & MCTD ✅ Screen RA / SjD / IIM if risk factors present 📌 Baseline risk assessment Assess globally using: • HRCT extent/pattern • FVC + DLCO • Autoantibodies • CRP/ESR • Clinical severity 📌 Monitoring 🔁 PFTs every 3–6 months initially, then 6–12 monthly 🔁 HRCT: • SSc/RA: every 1–2 yrs • IIM (high-risk): as early as 3–6 months 📌 Treatment recommendations 🟢 SSc-ILD • Tocilizumab (strong) • MMF / Rituximab / Cyclophosphamide (conditional) • Nintedanib for progressive fibrosis • MMF + Nintedanib combination allowed 🟢 IIM-ILD • Immunosuppression strongly recommended 🟢 RA / SjD / SLE / MCTD-ILD • Immunosuppressants suggested • RA-ILD (UIP): Pirfenidone may help 🟢 Progressive fibrosing CTD-ILD • Add Nintedanib 🚫 Lung biopsy NOT routine ✅ BAL only if infection / alternate dx suspected ✅ PROMs + 6MWT for severity/prognosis ⸻ 🔥 TAKE-HOME MESSAGE Early HRCT screening + structured monitoring + timely immunosuppression/antifibrotics = cornerstone of CTD-ILD care. Missing ILD = missed survival opportunity. ⸻ 📄 Eur Respir J 2026 DOI: 10.1183/13993003.02533-2024 #CTDILD #InterstitialLungDisease #Rheumatology #Pulmonology #SystemicSclerosis #RA #Myositis #Sjogrens #SLE #ERS #EULAR #ILD #MedTwitter #RheumTwitter #PulmTwitter
4
83
1
227
11,092
Alain Sanchez, MD retweeted
Volver a México y compartir con colegas siempre es una alegría: colegas increíbles, preguntas buenísimas y mucha conversación. Gracias al Colegio Mexicano de Reumatología por la invitación. 🇲🇽
3
13
732
Alain Sanchez, MD retweeted
Call for new applicants for Rheum With a (re)View—a mentoring program focused on cultivating manuscript reviewers for the ACR’s 3 scientific journals. ACR/ARP members with research experience are encouraged to apply by March 31 ▶️ Details → rheumatology.org/acr-journal…
1
5
640
🆕 2025 ACR Guideline for Treatment of Systemic #Lupus Erythematosus 🦋 Just Released: Nov 3 #ACR25 🔥 🔸Review organ-specific treatment recommendations 🔸Steroid & HCQ Use Guidance ➠ Read the Full Guideline: acr.tw/47mkegj #RheumX #RheumTwitter #Rheum @RheumNow
2
117
3
318
33,180
Alain Sanchez, MD retweeted
Now published: The 2025 ACR Guideline for the Treatment of Systemic Lupus Erythematosus 📄 Read the paper: acr.tw/47mkegj ℹ️ See additional content and resources on this guideline at acr.tw/4mbHK4W
1
128
329
21,627
Over 20 years have passed since the ACR last issued a broad treatment guideline for #SLE. In our NEWEST episode, Lisa R. Sammaritano, MD, summarizes the major updates in the soon-to-be-released 2025 guideline.🎙️LISTEN → acr.tw/4mTmpNi
8
1
14
869
#ESOC2025 🏃🏻‍♀️ESCAPE MEVO sub analysis 👉🏻 prognosis by image 🧠 👉🏻EVT <12 hs not > good functional outcome 👉🏻 Good collateral status > benefit 👉🏻 ⏱️<180 min > benefit
1
28
2
71
6,070
Alain Sanchez, MD retweeted
1/ 🧵The 2024 ACR Guidelines for Lupus Nephritis (LN) are here! Big shifts in screening, combo therapy, and steroid minimization. Let's break it down. Full text: acrjournals.onlinelibrary.wi…
1
53
4
123
12,478
Alain Sanchez, MD retweeted
Now published simultaneously in AC&R + A&R, the 2024 ACR Guideline for the Screening, Treatment, and Management of Lupus Nephritis See ACR guideline page for resources - rheumatology.org/lupus-guide… DOI link - doi.org/10.1002/acr.25528 Download the article - acr.tw/44sRwJM
1
70
8
175
53,534
Alain Sanchez, MD retweeted
Welcome Jaime! 🤩⭐️🤩⭐️
Grateful and ready for the new adventure!
2
2
38
7,311
Alain Sanchez, MD retweeted
Rheumatologist when someone automatically calls an ANA (+) “undifferentiated connective tissue disease”
2
7
1
28
4,846
NEW! Curious about how genetics influence autoimmune disease risk? Tune in & hear from @HocaogluMd, who dives into the study of antinuclear antibody production using data from the All of Us Research Program → acr.tw/42d7QN2 @ACR_Journals
6
8
1,084
Alain Sanchez, MD retweeted
🔟 Final Takeaways ✅ Obi improved renal outcomes in active LN ✅ Steroid-sparing effect (more Obi pts tapered to ≤7.5 mg/day) ✅ Proteinuria reduction = better long-term kidney survival ✅ Infections (esp. COVID-19) are a key safety concern
2
5
19
1,088
Alain Sanchez, MD retweeted
🚨 Breaking down the REGENCY trial 🚨 A Phase 3 RCT evaluating obinutuzumab (Obi) in lupus nephritis (LN). Let's dive into the study design, key findings, and the dosing regimens! 🧵⬇️
3
36
1
111
13,698
Alain Sanchez, MD retweeted
🚨 New Review Alert! 🚨 Dive into the evolving landscape of glucocorticoid therapy for lupus nephritis: 🔍 Historical shifts from high-dose to safer, low-dose strategies 🧬 Mechanisms, efficacy, & risks explored ⚖️ Balancing treatment efficacy with long-term safety
Now online in @NDTsocial Optimal Glucocorticoid Therapy in Lupus Nephritis 🧐The review examines different dosing strategies, including IV pulse and oral regimens, and presents evidence of their efficacy and safety. ▶️academic.oup.com/ndt/article…
1
13
1
44
4,450
Alain Sanchez, MD retweeted
Usually everything from @drlalonares is quite interesting. This was not the exemption #ACR24
👉🏼Presenting our recent work: Characterization of the Tissue Fibroblast Repertoire in IgG4-Related Ophthalmic Disease @FuruzawaJanette #ACR24 #ACR2024 #IgG4RD @IgG4ward @ReumaJoven @PanlarJ
1
2
648
Alain Sanchez, MD retweeted
99
2
266
26,951